• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Novel Avian-Origin Influenza A (H7N9) in Critically Ill Patients in China

tetano

Editor, Senior Moderator
Crit Care Med. 2014 Oct 31. [Epub ahead of print]
Novel Avian-Origin Influenza A (H7N9) in Critically Ill Patients in China.
Yang Y1, Guo F, Zhao W, Gu Q, Huang M, Cao Q, Shi Y, Li J, Chen J, Yan J, Jin Z, Wang X, Deng Y, Sun L, Cai H, Huang J, Zheng Y, Li W, Liu A, Chen B, Zhou M, Qiu H, Slutsky AS.
Author information
Abstract
OBJECTIVES::

In March 2013, human infection with a novel avian-origin reassortment influenza A (H7N9) virus was identified in China. A total of 26 cases were confirmed and treated in Jiangsu. All the patients had findings consistent with pneumonia and were admitted to an ICU, which pose a threat to human health. We aimed to provide the clinical features, treatment, and prognosis of the critically ill patients with H7N9 viral infection.
DESIGN::

A retrospective cohort study.
SETTING::

Eight closed ICUs in general hospitals distributed throughout the Jiangsu Provincial, China.
PATIENTS::

Patients infected with influenza A (H7N9) virus from March 20, 2013, through May 1, 2013, in Jiangsu Province were included.
INTERVENTIONS::

None.
MEASUREMENTS AND MAIN RESULTS::

Twenty-seven patients infected with H7N9 virus were identified in Jiangsu. Of these, 26 were hospitalized. The median age was 54.5 years, and 18 patients (69.2%) were men. The most common symptoms at the onset of illness were high fever and cough. White cell counts were normal or decreased. All the patients had findings consistent with pneumonia. Twenty-four patients (92.3%) developed acute respiratory distress syndrome, and 10 (38.5%) developed septic shock quickly after the onset of illness. Treatment with antiviral drugs was initiated in all the patients at a median of 8 days after the onset of illness. Mortality was 19.2% at 28 days and 30.8% at 90 days. Based on multiple logistic regression analysis, septic shock associated with severe hypoxemia was the only independent risk factor for mortality.
CONCLUSIONS::

Infection with novel avian-origin reassortment influenza A (H7N9) virus is characterized by high fever, cough, and severe respiratory failure and is associated with a high mortality. These data provide some general understandings for the early identification, ICU treatment, and short-term prognosis of hospitalized critical patients with H7N9.

PMID:
25365721
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25365721
 
Back
Top Bottom